OBR Daily Commentary

forumImage

Amgen Plans to Team Up With Watson on Generics

(New York Times) Dec 19, 2011 - Amgen, the biotechnology company, is planning to develop generic versions of some best-selling drugs.

Read Article arrow

Winston Wong, PharmD (Posted: December 20, 2011)

quotesThis just adds fuel to the Biosimilar vs generic discussion. One would think that since they are looking at producing generics (biosimilars) of their own drug, one would be lead to believe that maybe they will indeed be true generics. Of course, the ultimate question is will these products be an expensive biosimilar, or a less costly generic.quotes

Add Comment 1 Comment
forumImage

F.D.A. Revokes Approval of Avastin as Breast Cancer Drug

(New York Times) Nov 18, 2011 - The commissioner of the Food and Drug Administration on Friday revoked the approval of the drug Avastin as a treatment for breast cancer, ruling in an emotional issue that pitted the hopes of some desperate patients against the statistics of clinical trials.

Read Article arrow

Winston Wong, PharmD (Posted: November 18, 2011)

quotesThis clearly sets up an interesting scenario. There is really no clear direction here with CMS stating that they will continue with their National Coverage Decision to cover Avastin for Metastatic Breast Cancer. As well, the FDA counterpart in Europe made the completely opposite determination. It will be interesting to see where NCCN and ASCO will fall on this topic. We already have seen payors move their Medical Policies to be consistent with the FDA pre-determination, while others were awaiting this decision. The Crystal Ball is very cloudy these days.quotes

Add Comment 1 Comment
forumImage

Amgen Agreement on Anemia Drug

(NYT/Prescriptions blog) Nov 18, 2011 - Moving to protect a lucrative monopoly against impending competition, Amgen has reached an agreement that will preserve its status as the main supplier of anemia drugs to one of the nation’s two large kidney dialysis chains.

Read Article arrow

Winston Wong, PharmD (Posted: November 18, 2011)

quotesI wonder if the deep rebates DaVita is receiving from Amgen will be passed down to the payors to lower our cost?quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...